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a b s t r a c t
The Czech Republic presents one of the highest incidences of colorectal cancer in the world. We genotyped
10 single nucleotide polymorphisms in five DNA mismatch repair genes in 614 colorectal cancer cases and
614 matched controls from this country. The carriers of T-allele of the hMSH6-556G > T polymorphism
were at increased risk of colorectal cancer (OR 1.29; 95% CI 1.02–1.62). The stratification of data showed
that risk associated with the polymorphism was confined to rectal cancer (OR 1.42; 95% CI 1.03–1.95). The
A-allele of the Ex1 − 145G > A polymorphism in the hMSH6 gene was associated with a decreased risk of
colorectal cancer (OR 0.76; 95% CI 0.60–0.98). The C-allele of the IVS4-101G > C polymorphism in hMSH6
was associated with an increased risk of colon cancer (OR 1.34; 95% CI 1.03–1.74). The carriers of the
variant allele for the polymorphism IVS9-1406C > T in hMLH1 exhibited a decreased risk of rectal cancer
(OR 0.71; 95% CI 0.51–0.98). We observed a differential distribution of haplotypes based on three hMSH6
polymorphisms (-556G > T-Ex1 − 145G > A-IVS4-101G > C) in the cases and controls (global P = 0.02). The
TAG haplotype was associated with a decreased risk of colorectal cancer (OR 0.74; 95% CI 0.59–0.92),
whereas the most frequent haplotype GGG was associated with increased risk of rectal cancer (OR 1.32;
95% CI 1.05–1.65). However, multiple hypotheses testing diminishes a statistical significance of above
associations. Our data suggest a limited role for the investigated individual variants in mismatch repair
genes for the susceptibility to the disease. The haplotypes covering hMSH6 gene may, however, be involved
in risk modulation in this population.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
The mismatch repair (MMR) system plays a key role in main-
tenance of genomic stability through removal of mismatched
nucleotide pairs and insertion/deletion heterologies generated dur-
ing DNA replication. The components of DNA MMR machinery
are also involved in cell cycle arrest and induction of apoptosis
in response to different types of DNA damage [1,2]. Inactivation
of MMR is associated with hereditary and sporadic human can-
cers either through occurrence of mutations or through epigenetic
silencing of the component genes, leading to microsatellite insta-
∗ Corresponding author. Tel.: +420 241 062 694; fax: +420 241 062 782.
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bility (MSI) [3]. Both germline mutations and hypermethylation in
MMR genes have been reported in familial/hereditary forms of col-
orectal cancer (CRC). In the majority of sporadic CRC with MSI,
a hypermethylation of the hMLH1 promoter is considered to be
the main mechanism of MMR inactivation. However, the impact of
genetic and epigenetic mutations of MMR genes for the risk of spo-
radic form of CRC is currently quite indeterminate [4]. It is possible
that the common variants in relevant genes encoding DNA MMR
enzymes also impact the risk of the sporadic form of the disease on
a population level.
The recent discovery, through genome-wide association scans,
of a number of polymorphisms and loci associated with the disease
susceptibility has provided insight into the role of low penetrance
variants in the disease aetiology [5,6]. The latter report provides
further evidence for “common disease—common variant” model of
CRC predisposition.
0027-5107/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
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The genetic phenomena associated with MMR insufficiency in
CRC, such as MSI and loss of heterozygosity leading to “mutator
phenotype”, have been extensively studied [2,7]. The investigations
on the role of genetic polymorphisms for the disease susceptibil-
ity in population have lagged for a number of reasons that include
lack of proper design with sufficient sample sizes. Moreover, the
functional relevance of majority of polymorphisms in the genes
involved in MMR is not known. Though recent studies suggest an
influence of single nucleotide polymorphisms (SNPs) on biochem-
ical interaction between components of the MMR pathway or on
epigenetic mediated functional regulation [8,9]. In view of the well-
defined role of defective MMR in CRC, it is important to determine
if common variants in the involved genes affect susceptibility to the
disease at a population level.
CRC is one of the most common cancers in developed coun-
tries [10], accounting annually for 1,200,000 newly diagnosed cases
and over 525,000 deaths worldwide [11]. In a hospital-based case-
control study on the Czech population we investigated 10 SNPs
in MMR genes hMLH1, hMSH2, hMSH3, hMSH6, and hEXO1. The
selected variants included tagging SNPs for the hMLH1 and hMSH6
genes. CRC represent a major health problem in the Czech Republic
with incidence rate being one of the highest in the world [11].
2. Material and methods
2.1. Study population
The study population consisted of 614 CRC patients and 614 hospital-based con-
trols, matched for sex and age. The eligibility criteria for participation in the study
were that subjects were aged 29 years or more, were of Czech origin, and consented
to provide biological samples for genetic analysis. The cases were recruited from
nine oncological departments (two in Prague, one in Benesov, Brno, Liberec, Ples,
Pribram, Usti nad Labem, and Zlin), covering nearly the entire country, between
September 2004 and February 2006. The final inclusion of cases into the study was
based on the histological confirmation of the diagnosis. During the study period, a
total of 968 cases with CRC provided blood samples in above hospitals. Sixteen indi-
viduals were excluded as they fulfilled the Amsterdam criteria I and II for hereditary
CRC. The data of 952 subjects were used for matching with controls.
Controls were recruited in parallel among individuals admitted to five large
gastroenterological departments all over the Czech Republic (Prague, Brno, Jihlava,
Liberec, and Pribram). Each control subject was undergoing colonoscopy for various
gastrointestinal complaints. The reasons for colonoscopical investigation were (i)
macroscopic bleeding; (ii) positive Fecal Occult Blood Test (FOBT); (iii) abdominal
pain of unknown origin. Due to the high incidence of CRC in the Czech Republic,
colonoscopy is largely recommended and practiced. The control group was com-
posed of subjects with negative colonoscopic results for malignancy or idiopathic
bowel diseases [12]. To reduce selection bias, we included as controls only those
subjects with no previous diagnosis and without any chronic disease or those repeat-
edly admitted to hospital and modified habits because of their disease. Among 739
recruited controls, a total of 663 (89.7%) were used for matching for sex and age
with CRC patients. As a result, 614 case-control pairs were formed. Thus, 338 cases
and 49 controls not fitting into the pairs or with incomplete lifestyle and potential
risk factor information were excluded from initial groups. The sex distribution in
excluded controls was similar to those included.
The participating subjects were properly informed and provided a written con-
sent and approval for genetic analysis. The study-design was approved by the Ethical
Committee of the Institute of Experimental Medicine, Prague, Czech Republic.
2.2. Interviews
Cases and controls were interviewed by trained personnel using a structured
questionnaire to determine demographic characteristics and potential risk factors
for CRC. Study subjects provided information on their lifestyle habits, body mass
index (BMI), diabetes, and family/personal history of cancer. Lifelong or long-term
(at least six consecutive months) drug use was included in the questionnaire.
2.3. SNP selection and genotyping
For this study we chose 10 SNPs in MMR genes hMLH1, hMSH2, hMSH3, hMSH6
and hEXO1. The selected polymorphisms were located in coding and non-coding
regions of the genes and exerted a possible functional effect according to results of
association and/or in vitro studies. The polymorphism studied were: two SNPs in
non-coding regions of the hMLH1 gene (the -93G > A in promoter (rs1800734) and
the IVS9-1406C > T (rs4647269) polymorphism in intron 9); two nucleotide changes
in the hMSH2 (the SNP located in the end of intron 12 IVS12-6T > C (rs2303428)
and a missense variant Ex6 + 23G > A (rs4987188) coding the Gly322Asp amino acid
change); two exonic SNPs in the hMSH3 gene (Ex4-100G > A (rs1805355, Pro231Pro)
in exon 4 and Ex23 + 3G > A (rs26279) in exon 23 coding the Ala1045Thr amino acid
substitution); two SNPs in the hMSH6 gene -556G > T (rs3136228) located in the
promoter region and Ex1 − 145G > A (rs1042821, Gly39Glu) in exon 1 and a SNP in
the EXO1 exon 12 (Ex12 + 49C > T; rs4149963) coding Thr439Met amino acid sub-
stitution. Two tagging SNPs the IVS9-1406C > T (rs4647269) polymorphism in the
hMLH1 gene and the IVS4-101G > C (rs2072447) in the hMSH6 gene, capturing 21 and
2 SNPs, respectively, were selected based on Hapmap data (www.hapmap.org) for
corresponding haplotypes reconstruction. All studied SNPs (with exception of more
rare Ex6 + 23G > A polymorphism in hMSH2, MAF = 0.03) are common in Caucasians
(MAF 0.06–0.53) according to Hapmap and SNP500 databases.
DNA was isolated from peripheral blood lymphocytes of CRC patients and con-
trol subjects using phenol–chloroform procedure and stored at −20 ◦C. The purity
was assessed by spectrophotometry. Pre-designed assays for allelic discrimination
(Taqman) were used to genotype eight out of the ten selected SNPs. The ampli-
fication for genotyping was performed on an AB 7500 Real-Time PCR (Applied
Biosystems, Foster City, USA) system. For polymorphisms Ex6 + 23G > A (rs4987188)
in the hMSH2 gene and Ex1 − 145G > A (rs1042821) in the hMSH6 gene we used
a PCR-RFLP method due to non-availability of pre-designed assays for allelic dis-
crimination. The genotyping for the Ex6 + 23G > A polymorphism in the hMSH2
gene was carried out as previously described [13]. For genotyping the Ex1 − 145
G > A polymorphism in the hMSH6 gene following primers were designed using
Primer3 v.0.4.0 (http://frodo.wi.mit.edu): sense 5′-AGATGCGGTGCTTTTAGGAG-3′ ,
antisense 5′-CCCTCCGTTGAGGTTCTTC-3′ . Each PCR reaction (20 l) contained 50 ng
of genomic DNA, 1 U of HOT FIREPol DNA polymerase I, 25 mM Tris–HCl, 50 mM KCl,
2.5 mM MgCl2, 300 M dNTPs, and 0.3 M of each primer. Thermal cycle conditions
were as suggested by manufacturer (Odex, Lucca, Italy): 95 ◦C 15 min, 20 cycles (95 ◦C
1 min, 68 ◦C 30 s—1 ◦C/cycle, 72 ◦C 1.5 min), 20 cycles (95 ◦C 1 min, 51 ◦C 30 s, 72 ◦C
1.5 min), 72 ◦C 10 min. The 289 bp PCR product was digested with 6 U of restriction
enzyme SmaI (New England BioLabs Inc., USA) overnight. The G allele was digested
into 114 and 175 bp fragments, whereas the A variant remained intact. The digested
PCR products were resolved on 2% agarose gel with ethidium bromide and visualized
under UV light.
The genotype screening was performed simultaneously for cases and controls.
Approximately 10% of the samples were re-genotyped for each of ten polymorphisms
analysed to confirm the initial results.
2.4. Statistical analyses
Genotype distribution for each polymorphism in controls was tested for devia-
tion from the Hardy–Weinberg equilibrium by Pearson chi-square test. Differences
in baseline socio-demographic characteristics between cases and controls were
analysed using chi-square test and Student’s t-test. Multivariate logistic regressions
were used to examine the association between each genotype and risk of selected
health endpoints (all CRC, colon cancer, and rectal cancer separately). Odds ratio
(OR) and 95% confidence interval (CI) were estimated including gender and age
as covariates. Separate analyses were carried out following the stratifications for
smoking and for tumor localization.
The haplotype frequencies in cases and controls were inferred with the
SAS/Genetics software module. The analysis was carried out to examine the phase
of hMLH1, hMSH2, hMSH3 and hMSH6 polymorphisms, using the expectation–
maximization algorithm to generate maximum likelihood estimates of haplotype
frequencies.




A modulating role of 10 polymorphisms in MMR genes and their
haplotypes on a risk of CRC (as well as colon and rectal cancers sep-
arately) was investigated using a case-control approach (Table 1).
Sex and age were chosen as main criteria for matching cases and
controls. A preliminary analysis revealed that there were no major
significant differences for the considered covariates between the
patients and controls, with the exception of a moderately different
distribution of ex-smokers (defined as individuals who quit smok-
ing less than 5 years prior to the sampling). A statistically significant
difference was observed in dietary habits between the cases and
controls with prevailing vegetarians among cases. Moreover, con-
trols showed a higher percentage of individuals with higher degree
of education as compared to cases.
Author's personal copy
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Table 1
Characteristics of CRC patients and control subjects.




Age at diagnosis (years)




Colon cancer 217 –
Sigmoidal 156 –
Rectal cancer 241 –
Colon + Sigm. 373 –
Cancer family history (%)
Positive history 54.2 59.7
Negative history 45.8 40.3
Smoking status (%)
Non-smokers 51.1 53.4
Ex-smokers >5 years 22.1 20.9
Ex-smokers <5 years 10.6 4.4
Current smokers 16.2 21.3
No of cigarettes (%)
<20 cig/day 58.0 59.4









City + Country 14.7 19.5
Country 28.6 25.9
Education (%)
Basic school 34.8 28.5
High school 51.5 53.2
University 13.7 18.3
Body mass index
Mean ± S.D. 26.7 ± 4.4 27.0 ± 4.5
<18.5 (%) 1.5 0.4
18.5–24.9 (%) 36.6 35.0
25.0–29.9 (%) 43.1 43.1
30.0–39.9 (%) 17.8 19.9
>40 (%) 1.0 1.6
3.2. Genotype analyses
The genotype distribution of polymorphisms analysed in
this study did not show statistically significant deviation from
the Hardy–Weinberg equilibrium. The data on allele and geno-
type distributions in CRC cases and controls, and the sex and
age adjusted ORs for associated risk are presented in Table 2.
The minor allelic frequencies (MAF) for polymorphisms in the
MMR genes in the Czech population were in concordance with
those reported for Caucasian population in the public HAPMAP
(http://www.hapmap.org/citinghapmap.html.en) or SNP500
databases (http://snp500cancer.nci.nih.gov/terms ethnic.cmf).
Two polymorphisms in the hMSH6 gene showed an association
with altered risk of CRC (P ≤ 0.05). Carriers of variant allele for the
-556G > T polymorphism in the promoter region of the gene were
at an increased risk of CRC (OR 1.29; 95% CI 1.02–1.62; P = 0.04),
whereas the carriers of the variant A-allele for the -145G > A poly-
morphism in the hMSH6 exon 1 were at a decreased risk of CRC.
Table 2
Distribution of MMR genotypes in CRC patients and controls and results of uncon-
ditional logistic regression analysisa.
Genotype Casesb Controlsb OR CI 95% Pc
hMLH1-93G > A (rs1800734)
GG 359 365 1 (ref) – 0.75
GA 216 209 1.10 0.86–1.40
AA 34 37 1.00 0.61–1.64
GA + AA 250 246 1.10 0.86–1.36 0.50
hMLH1 IVS9-1406C > T (rs4647269)
CC 193 172 1 (ref) – 0.21
CT 304 317 0.83 0.64–1.08
TT 107 119 0.75 0.54–1.05
CT + TT 411 436 0.81 0.63–1.04 0.10
hMSH2 IVS12-6T > C (rs2303428)
TT 505 516 1 (ref) – 0.59
TC 102 89 1.16 0.85–1.58
CC 4 3 1.46 0.32–6.57
TC + CC 106 92 1.17 0.86–1.59 0.32
hMSH2 Ex6 + 23G > A (rs4987188)
GG 586 588 1(ref) – 0.70
GA 20 22 0.89 0.47–1.66
AA 0 0 – – –
hMSH3 Ex4-100G > A (rs1805355)
GG 507 531 1 (ref) – 0.56
GA 92 73 1.36 0.97–1.91
AA 7 6 1.28 0.43–3.84
GA + AA 99 79 1.36 0.98–1.88 0.07
hMSH3 Ex23 + 3G > A (rs26279)
GG 302 307 1 (ref) – 0.74
GA 265 256 1.07 0.85–1.36
AA 41 47 0.93 0.59–1.46
GA + AA 306 303 1.05 0.84–1.32 0.67
hMSH6-556G > T (rs3136228)
GG 225 254 1 (ref) – 0.10
GT 293 272 1.26 0.98–1.62
TT 94 85 1.36 0.96–1.93
GT + TT 387 357 1.29 1.02–1.62 0.04
hMSH6 Ex1 − 145G > A (rs1042821)
GG 428 399 1(ref) – 0.08
GA 153 181 0.78 0.61–1.01
AA 20 29 0.63 0.35–1.14
GA + AA 173 210 0.76 0.60–0.98 0.03
hMSH6 IVS4-101G > C (rs2072447)
GG 278 306 1 (ref) – 0.29
GC 268 253 1.18 0.93–1.50
CC 59 51 1.26 0.83–1.90
GC + CC 327 304 1.20 0.95–1.50 0.13
hEXO1 Ex12 + 49C > T (rs4149963)
CC 479 497 1 (ref) – 0.43
CT 123 106 1.21 0.90–1.62
TT 7 7 0.91 0.30–2.73
CT + TT 130 113 1.19 0.90–1.58 0.23
OR, odds ratio; CI 95%, confidence interval; ref., reference.
a Adjusted for sex and age.
b Numbers may not add up to 100% of subjects due to genotyping failure. All
samples that did not give a reliable result in the first round of genotyping were
resubmitted to up to three additional rounds of genotyping. Data points that were
still not filled after this procedure were left blank.
c Bold values indicate P ≤ 0.05; no significant difference in genotype distributions
were recorded after correction for multiple hypotheses testing.
The data stratification based on the tumor location showed that
the increased risk associated with the variant allele of the -556G > T
polymorphism in the hMSH6 promoter was more pronounced for
rectal cancer (OR 1.42; 95% CI 1.03–1.95; P = 0.03) than for colon
cancer (OR 1.21; 95% CI 0.92–1.58; P = 0.17; Table 3). In addition, we
found that in the hMSH6 gene the variant allele of the intronic IVS4-
101G > C SNP was associated with increased risk of colon cancer (OR
Author's personal copy
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Table 3
Distribution of genotypes in MMR genes and results of unconditional logistic regression analysisa for CRC patients stratified for tumor location and controls.
Genotype Controlsb Colonb OR CI 95% P Rectumb OR CI 95% Pc
hMLH1-93G > A
GG 365 142 131
GA + AA 246 228 0.96 0.73–1.25 0.74 108 1.31 0.96–1.78 0.09
hMLH1 IVS4-101G > C
CC 172 111 82
CT + TT 436 257 0.89 0.67–1.19 0.43 154 0.71 0.51–0.98 0.04
hMSH2 IVS12-6T > C
TT 516 309 196
TC + CC 92 62 1.12 0.79–1.6 0.53 44 1.24 0.83–1.85 0.30
hMSH2 Ex6 + 23G > A
AA 588 356 230
GA 22 13 0.92 0.45–1.89 0.82 7 0.82 0.35–1.95 0.66
hMSH3 Ex4-100G > A
GG 531 309 198
GA + AA 79 59 1.33 0.92–1.93 0.13 40 1.38 0.9–2.11 0.14
hMSH3 Ex23 + 3G > A
GG 307 196 106
GA + AA 303 172 0.90 0.69–1.17 0.44 134 1.34 0.98–1.81 0.06
hMSH6-556G > T
GG 254 144 81
GT + TT 357 228 1.21 0.92–1.58 0.17 159 1.42 1.03–1.95 0.03
hMSH6 Ex1 − 145G > A
GG 399 259 169
GA + AA 210 107 0.78 0.59–1.03 0.08 66 0.74 0.53–1.03 0.08
hMSH6 IVS4-101G > C
GG 306 158 120
GC + CC 304 209 1.34 1.03–1.74 0.03 118 1.02 0.75–1.38 0.92
hEXO1 Ex12 + 49C > T
CC 497 285 194
CT + TT 113 85 1.31 0.95–1.81 0.10 45 1.03 0.7–1.51 0.89
OR, odds ratio; CI, 95%, confidence interval; ref., reference.
a Adjusted for sex and age.
b Numbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were resubmitted
to up to three additional rounds of genotyping. Data points that were still not filled after this procedure were left blank.
c Bold values indicate P ≤ 0.05; no significant difference in genotype distributions were recorded after correction for multiple hypotheses testing.
1.34; 95% CI 1.03–1.74; P = 0.03). On the other hand, carriers of the
T-allele for the IVS9-1406C > T polymorphic variant hMLH1 exhib-
ited a decreased risk of rectal cancer (OR 0.71; 95% CI 0.51–0.98;
P = 0.04). However, by correcting for multiple hypotheses testing
the above associations are not convincingly significant.
The data analysis did not show any association with either smok-
ing habit or family history of CRC with any of the polymorphisms
in the MMR genes included in this study (data not shown).
3.3. Haplotype analyses
By constructing haplotypes for four MMR genes, we observed a
statistically significant difference in the hMSH6 haplotype distribu-
tion between the CRC cases and controls (global test P = 0.02). The
TAG haplotype (-556G > T-Ex1 − 145G > A-IVS4-101G > C) was asso-
ciated with decreased risk of CRC in the studied population (Table 4;
OR 0.74; 95% CI 0.59–0.92). None of the haplotypes in the hMLH1,
hMSH2, or hMSH3 genes was significantly associated with risk of
CRC (global tests for hMLH1 P = 0.11, hMSH2 P = 0.59, and for hMSH3
P = 0.31).
The analysis of hMSH6 haplotype distribution after the stratifica-
tion for tumor localization (Table 5) revealed significant differences
between controls and patients with rectal cancer in particular
(global P-value 0.03). Global P-value for haplotype effect on colon
cancer (0.12) did not reflect significant differences in haplotype
distribution between the cases and controls. The TAG haplotype
for hMSH6 (-556G > T-Ex1 − 145G > A-IVS4-101G > C) was associ-
ated with significantly decreased risk in both colon and rectal
cancer patients (Table 5; OR 0.74; 95% CI 0.51–0.96 and OR 0.73;
95% CI 0.53–1.00, respectively). The GGG haplotype was found to be
exclusively associated with increased risk of rectal cancer (OR 1.32;
95% CI 1.05–1.65). None of the MMR haplotypes was significantly
associated with the familial aggregation of the disease.
The linkage disequilibrium (LD) between the three loci anal-
ysed in the hMSH6 gene (-556G > T-Ex1 − 145G > A-IVS4-101G > C)
is shown in Fig. 1.
Table 4
Distribution of hMSH6 haplotypes in patients with CRC and in controls.
Haplotypea Cases Nb Controls Nb OR CI 95% P-valuec
TGG 180 218 0.84 0.68–1.05 0.02
TGC 350 322 1.16 0.96–1.39
TAG 165 217 0.74 0.59–0.92
TAC 17 16 1.07 0.51–2.25
GGG 452 413 1.16 0.98–1.30
GGC 12 13 0.93 0.4–2.18
GAG 8 3 2.70 0.65–12.86
a hMSH6-556G > T-Ex1 − 145G > A-IVS4-101G > C.
b N is the number of alleles. Because each individual has two alleles, the total
number of alleles will be twice the total number of individuals. Individuals missing
haplotype data were not included in the analyses.
c Global P-value for haplotype effect calculated from 2 test. Significant ORs are
in bold.
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Table 5
Distribution of hMSH6 haplotypes in CRC patients stratified for tumor location and in controls.
Haplotypesa Controls Nb Colon cancer cases Nb OR (CI 95%)c P-valuec Rectum cancer cases Nb OR (CI 95%)c P-valuec
TGG 218 114 1.03 (0.80–1.33) 0.12 66 1.35 (0.97–1.85) 0.03
TGC 322 217 1.17 (0.95–1.45) 132 1.06 (0.83–1.36)
TAG 217 101 0.74 (0.51–0.96) 64 0.73 (0.53–1.00)
TAC 16 13 1.36 (0.61–3.00) 4 0.65 (0.18–2.08)
GGG 413 264 1.10 (0.90–1.34) 188 1.32 (1.05–1.65)
GGC 13 9 1.15 (0.45–2.90) 3 0.60 (0.14–2.25)
GAG 3 4 2.23 (0.42–12.52) 4 3.50 (0.66–19.69)
a hMSH6-556G > T-Ex1 − 145G > A-IVS4-101G > C.
b N is the number of alleles. Because each individual has two alleles, the total number of alleles will be twice the total number of individuals. Individuals with missing
haplotype data were not included in the analyses.
c Global P-value for haplotype effect calculated from 2 test. Significant ORs are in bold.
Fig. 1. Linkage disequilibrium |D′ | (R2) between polymorphisms in the hMSH6 gene.
4. Discussion
We investigated variants in the genes encoding proteins
involved in DNA MMR and their role in modulating susceptibility
to CRC using a case-control approach. An analysis of questionnaire-
based lifestyle data revealed a significant difference in dietary
habits in cases with prevailing vegetarians as compared to controls.
However, hardly any far-reaching conclusions may be drawn based
on this observation due to the subjectivity of questionnaires which
decreases reliability of the given information. Moreover, as dis-
cussed recently [14], questionnaire-based observations introduce
profound bias due to dietary recall and influence of confounders.
Dietary habits during lifetime may further be modulated, as conse-
quence of gastrointestinal or bowel diseases in particular [14].
Our data suggested an indication of possible association
between polymorphisms in the hMSH6 gene and risk of CRC. The
increased risk of CRC and, in particular, of rectal cancer, in asso-
ciation with the variant allele of the -556G > T polymorphism in
the hMSH6 promoter may be due to its modulating effect on tran-
scription. An in vitro study on CHO cells suggested that the same
sequence variation results in loss of Sp1 binding site involved in
the gene transcription regulation. In addition, -556T allele in com-
bination with two other polymorphisms in hMSH6 (-448G > A and
-159C > T), apparently affects gene expression by promoter methy-
lation [8]. However, no association of the -159C > T polymorphism
with CRC risk was reported in an independent study [15]. We
also found that the carriers of the variant allele for the -145G > A
polymorphism in the hMSH6 exon 1 coding for Gly39Glu amino
acid change exhibited a significantly lower risk of CRC than non-
carriers. This tendency was observed in patients with both colon
and rectal cancers. Previous studies did not find any association
of the same polymorphism with CRC risk [16] and with risk of
adenomatous polyposis in populations of Caucasian origin [17].
Glycine-to-glutamic acid substitution can determine the forma-
tion of sterically different helical structures, polypeptide folding,
and intrinsic aggregation due to hydrophilic side chain of glutamic
acid, thus affecting the protein function [18,19].
We found that the -93G > A SNP located in the core promoter
region of the hMLH1 gene had no effect on CRC susceptibility, even
though it has been demonstrated earlier to modulate the risk of
lung [20], breast [21], and endometrial cancers [22]. The -93G > A
polymorphism is located in a CpG island and the A-allele is presum-
ably involved in the epigenetic silencing of hMLH1, via promoter
methylation [9]. Recently, the presence of variant allele was sig-
nificantly associated with increased risk of MSI-unstable CRC [23].
One of the plausible reasons for not finding any association could be
that patients with CRC were not classified according to MSI status
in our study population. In general, MSI-unstable tumors account
for 15–20% of sporadic CRC malignancies [24].
In an earlier study, the intronic substitution IVS12-6T > C in the
hMSH2 gene was associated with predisposition to sporadic CRC in
a small European study [25]. However, our data did not show any
association for this polymorphism with the risk of the disease, in
concordance with studies carried out on a Korean population [26]
and on a population with mixed ethnicity from Canada [23]. The
coding polymorphism Ex6 + 23G > A in the hMSH2 gene may have
a putative influence on MMR function due to location in a region
stabilizing this gene’s interaction with hEXO1 protein [27] and was
considered as affecting breast cancer susceptibility [13], with no
significant association with CRC risk [28].
Few studies are available at present for other SNPs investigated
in the remaining genes, hMSH3 and hEXO1, for which we found no
significant associations. An association with increased CRC risk has
been shown for Ex23 + 3G > A polymorphism in hMSH3 in patients
of European descent [15,29] and Ex12 + 49C > T SNP in hEXO1 in a
Japanese population [30]. Both polymorphisms could have a puta-
tive functional effect since Ex23 + 3G > A cause Ala1045Thr amino
acid change in ATP-binding domain of hMSH3 and Ex12 + 49C > T
coding Thr439Met substitution in hEXO1 may influence interaction
between hEXO1 and hMLH1 proteins [27]. Although other polymor-
phisms in other MMR genes, such as hMLH3, hPMS1, and hPMS2
could be of relevance to the CRC risk [28,31–33], these were not
addressed in the current study.
Haplotype analysis represents a powerful approach in searching
for disease-causing alleles and in locating the underlying muta-
tions. We found that the haplotype TAG, based on three SNPs of the
hMSH6 gene (-556G > T-Ex1 − 145G > A-IVS4-101G > C), was associ-
ated with a decreased overall risk of CRC. We also observed that the
most frequent haplotype, GGG, was associated with an increased
risk of rectal cancer.
No unambiguous agreement could be presently reached about
the role of haplotypes in hMLH1, hMSH2, or hMSH3 genes. However,
for none of these genes we recorded a significant association with
sporadic CRC risk. The increased CRC risk was proposed for a rare
hMLH1 haplotype [29] and for hMSH3 haplotype constructed using
two SNPs in the gene including Ex23 + 3G > A [16].
To conclude, in our analysis of modulating effects of individual
MMR polymorphisms on sporadic CRC risk we found an indica-
tion of an association with polymorphisms and haplotypes in the
hMSH6 gene. Though, after correction for multiple hypotheses test-
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ing our results cannot be considered as statistically significant and,
thus, should not be overinterpreted. This is in line with the results
of recent studies describing a limited role of the common vari-
ants in the MMR genes hMLH1, hMSH2, hMSH3 and hMSH6 for CRC
risk [28,29]. Nevertheless, considering the importance of the MMR
genes in the etiology of CRC further studies with pooled data would
be imperative to determine if the common variants in the genes per
se or in combination with other variants play any role in the disease
pre-disposition.
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